Back to results
US 11,957,783 B2Granted
Topical immunosensitizers to treat viral and fungal infections
AssigneeSquarex Pharmaceutical Corporation
InventorsHugh McTavish, Thomas Dag Horn
Life of this patent
Estimating the term…
Abstract
A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.
Claims17
A method of treating a fungal infection comprising:
- applying a topical immunosensitizer to the skin or a mucous membrane of a person infected with a fungus and in recognized need of treatment for the fungal infection;
- wherein the applying step is done no more than 6 times in a 12 month period;
- wherein the topical immunosensitizer is squaric acid dibutyl ester (SADBE), a squaric acid ester, diphenylcyclopropenone (DPCP), 1-chloro-2,4-dinitrobenzene (DNCB), 1-chloro-2,6-dinitrobenzene, or urushiol;
- wherein if the fungal infection is an infection of the skin or mucous membrane the method does not comprise applying the topical immunosensitizer to at least some area or areas of diseased skin or diseased mucous membrane of the person arising from the fungal infection;
- and
- wherein the person is in recognized need of treatment for the fungal infection.
3 more elements
A method of treating molluscum contagiosum comprising:
- applying a topical immunosensitizer to the skin of a person infected with molluscum contagiosum pox virus and in recognized need of treatment for molluscum contagiosum;
- wherein the applying step is done no more than 6 times in a 12 month period and the method does not comprise any two incidences of the applying step within 6 weeks of each other;
- wherein the topical immunosensitizer is squaric acid dibutyl ester (SADBE);
- and
- wherein the method does not comprise applying the topical immunosensitizer to at least one or more molluscum contagiosum lesions of the person.
2 more elements
Dependencies are inferred from the claim text.